Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid. Biomed 101 binds to the leukotriene B4 receptor, but does not...
- Mechanism
- Curator reviewed
Biomed 101 binds to the leukotriene B4 receptor. Blocking this receptor it prevents adverse effects from interleukin-2. Recently, BioMedicines scientists have shown in clinical testing in patients with renal cancer that the therapeutic index of interleukin-2 is improved by the co- administration of Biomed 101. These patients are able to better tolerate interleukin-2 and experience fewer serious side effects.
- Primary indication
- Investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with Biomed 101, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account